These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 29027470)

  • 21. A survey of tools for variant analysis of next-generation genome sequencing data.
    Pabinger S; Dander A; Fischer M; Snajder R; Sperk M; Efremova M; Krabichler B; Speicher MR; Zschocke J; Trajanoski Z
    Brief Bioinform; 2014 Mar; 15(2):256-78. PubMed ID: 23341494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance comparison: exome sequencing as a single test replacing Sanger sequencing.
    Fridman H; Bormans C; Einhorn M; Au D; Bormans A; Porat Y; Sanchez LF; Manning B; Levy-Lahad E; Behar DM
    Mol Genet Genomics; 2021 May; 296(3):653-663. PubMed ID: 33694043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next generation sequencing in neonatology: what does it mean for the next generation?
    Janvier A; Barrington K; Lantos J
    Hum Genet; 2022 May; 141(5):1027-1034. PubMed ID: 35348890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do second generation sequencing techniques identify documented genetic markers for neonatal diabetes mellitus?
    Ali Khan I
    Heliyon; 2021 Sep; 7(9):e07903. PubMed ID: 34584998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic yield of next-generation sequencing in 87 families with neurodevelopmental disorders.
    Álvarez-Mora MI; Sánchez A; Rodríguez-Revenga L; Corominas J; Rabionet R; Puig S; Madrigal I
    Orphanet J Rare Dis; 2022 Feb; 17(1):60. PubMed ID: 35183220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Genetic analysis of hereditary hematological disorders: overview].
    Yoshida K; Ogawa S
    Rinsho Ketsueki; 2015 Jul; 56(7):861-6. PubMed ID: 26251150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children.
    Beale S; Sanderson D; Sanniti A; Dundar Y; Boland A
    Health Technol Assess; 2015 Jun; 19(46):1-90. PubMed ID: 26132578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New genes and pathomechanisms in mitochondrial disorders unraveled by NGS technologies.
    Legati A; Reyes A; Nasca A; Invernizzi F; Lamantea E; Tiranti V; Garavaglia B; Lamperti C; Ardissone A; Moroni I; Robinson A; Ghezzi D; Zeviani M
    Biochim Biophys Acta; 2016 Aug; 1857(8):1326-1335. PubMed ID: 26968897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WES/WGS Reporting of Mutations from Cardiovascular "Actionable" Genes in Clinical Practice: A Key Role for UMD Knowledgebases in the Era of Big Databases.
    Pinard A; Salgado D; Desvignes JP; Rai G; Hanna N; Arnaud P; Guien C; Martinez M; Faivre L; Jondeau G; Boileau C; Zaffran S; Béroud C; Collod-Béroud G
    Hum Mutat; 2016 Dec; 37(12):1308-1317. PubMed ID: 27647783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility in infants with suspected monogenic conditions through next-generation sequencing.
    Hong S; Wang L; Zhao D; Zhang Y; Chen Y; Tan J; Liang L; Zhu T
    Mol Genet Genomic Med; 2019 Jun; 7(6):e684. PubMed ID: 30968598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical application of next-generation sequencing for Mendelian diseases.
    Jamuar SS; Tan EC
    Hum Genomics; 2015 Jun; 9(1):10. PubMed ID: 26076878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NGS-Based genetic testing for heritable cardiovascular diseases. Specific requirements for obtaining informed consent.
    Schmidtke J; Wittkowski K; Glaubitz R
    Mol Cell Probes; 2019 Jun; 45():70-78. PubMed ID: 31059777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction to next-generation nucleic acid sequencing in cardiovascular disease research.
    Diaw L; Youngblood V; Taylor JG
    Methods Mol Biol; 2013; 1027():157-79. PubMed ID: 23912986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of Exome Sequencing to Identify Rare Genetic Diseases.
    Udupa P; Ghosh DK
    Methods Mol Biol; 2024; 2719():79-98. PubMed ID: 37803113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted 46-gene and clinical exome sequencing for mutations causing cardiomyopathies.
    Waldmüller S; Schroeder C; Sturm M; Scheffold T; Imbrich K; Junker S; Frische C; Hofbeck M; Bauer P; Bonin M; Gawaz M; Gramlich M
    Mol Cell Probes; 2015 Oct; 29(5):308-14. PubMed ID: 25979592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Archived neonatal dried blood spot samples can be used for accurate whole genome and exome-targeted next-generation sequencing.
    Hollegaard MV; Grauholm J; Nielsen R; Grove J; Mandrup S; Hougaard DM
    Mol Genet Metab; 2013; 110(1-2):65-72. PubMed ID: 23830478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular defects identified by whole exome sequencing in a child with atypical mucopolysaccharidosis IIIB.
    Zeng Q; Fan Y; Wang L; Huang Z; Gu X; Yu Y
    J Pediatr Endocrinol Metab; 2017 Apr; 30(4):463-469. PubMed ID: 28306536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opportunities and challenges of whole-genome and -exome sequencing.
    Petersen BS; Fredrich B; Hoeppner MP; Ellinghaus D; Franke A
    BMC Genet; 2017 Feb; 18(1):14. PubMed ID: 28193154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Disease Susceptibility Alleles in the Next Generation Sequencing Era.
    DiStefano JK; Kingsley CB
    Methods Mol Biol; 2018; 1706():3-16. PubMed ID: 29423790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next-generation sequencing in the clinic: promises and challenges.
    Xuan J; Yu Y; Qing T; Guo L; Shi L
    Cancer Lett; 2013 Nov; 340(2):284-95. PubMed ID: 23174106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.